drugset
drugset / Trial / NCT02786069

A Single-dose Escalation Safety and PK Study for PLC in Healthy Chinese

NCT02786069 ↗

Phase 1 Completed 16 enrolled Lee's Pharmaceutical Limited
NaSingle-groupOpen-labelTreatment

Summary

The main objective is to evaluate the effect of single dose Propionyl-L-Carnitine Hydrochloride on clinical pharmacokinetic characteristics and its effect of clinical pharmacokinetic characteristics and safety on healthy Chinese subjects to provide a basis for market authorization registration.

Timeline

Start
2015-06
Primary completion
2015-11
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject LEVOCARNITINE PROPIONATE Small molecule 1 g Oral
Subject LEVOCARNITINE PROPIONATE Small molecule 2 g Oral
Subject LEVOCARNITINE PROPIONATE Small molecule 4 g Oral

Indications

peripheral arterial disease